Aadil Najeed, Senior Resident at Government Medical College Srinagar, shared on LinkedIn:
“In many LMICs, patients with Stage III NSCLC cannot access durvalumab – not because it isn’t indicated, but because it is unaffordable.
Not a substitute for immunotherapy, but a question worth exploring: can we make cancer care more accessible?”
Commenting an older post:
“Adaptive SBRT boost after CCRT in Stage III NSCLC:
51 patients | 2-year OS: 61.5% | 2-year LRC: 62.8%.”
Title: Response-Adaptive Stereotactic Body Radiotherapy Boost After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC: A Prospective Single-Centre Cohort Study
Authors: Esin Kiraz, Celalettin Eroğlu, Mete Gündoğ, Oktay Bozkurt, Özgür Karabıyık, Ümmühan Abdülrezzak, Mustafa Tarkan Aksözen
You can also read:
Nikolaos A. Dallas: LiveWell Helps Us Build a More Accessible Lung Cancer Screening Pathway
